scholarly journals Conformational Change of Human Checkpoint Kinase 1 (Chk1) Induced by DNA Damage

2016 ◽  
Vol 291 (25) ◽  
pp. 12951-12959 ◽  
Author(s):  
Xiangzi Han ◽  
Jinshan Tang ◽  
Jingna Wang ◽  
Feng Ren ◽  
Jinhua Zheng ◽  
...  
2008 ◽  
Vol 7 (8) ◽  
pp. 2394-2404 ◽  
Author(s):  
Alessandra Blasina ◽  
Jill Hallin ◽  
Enhong Chen ◽  
Maria Elena Arango ◽  
Eugenia Kraynov ◽  
...  

2012 ◽  
Vol 12 (3) ◽  
pp. 194-201 ◽  
Author(s):  
Francoise M. Perron-Sierra ◽  
Nathalie Kucharkzyk ◽  
Celine Boucley ◽  
Christel Guyard-Daumas ◽  
Sophie Sciberras ◽  
...  

2018 ◽  
Author(s):  
Fabian Schuler ◽  
Sehar Afreen ◽  
Claudia Manzl ◽  
Georg Häcker ◽  
Miriam Erlacher ◽  
...  

ABSTRACTCheckpoint kinase 1 is critical for S-phase fidelity and preventing premature mitotic entry in the presence of DNA damage. Tumour cells have developed a strong dependence on CHK1 for survival and hence this kinase has developed into a popular drug-target.Chk1-deficiency in mice results in blastocyst death due to G2/M checkpoint-failure showing that it is an essential gene and may be difficult to target therapeutically without side-effects. Here, we show that chemical inhibition of CHK1 kills murine hematopoietic stem and progenitor cells (HSPCs) as well as human CD34+HSPCs by the induction of BCL2-regulated but p53-independent apoptosis. Moreover,Chk1is essential for stem cell survival and definite hematopoiesis in the mouse embryo. Remarkably though, cell death inhibition in hematopoietic stem cells (HSC) cannot restore blood cell formationin uteroasChk1loss causes severe DNA damage that ultimately prevents HSC expansion. Our findings establish a previously unrecognized role for CHK1 in establishing hematopoiesis; they also suggest adverse effects of therapeutic CHK1-inhibtion, particularly under conditions forcing stem cells out of dormancy, such as chemotherapy-induced myelosuppression.


2016 ◽  
Vol 90 (20) ◽  
pp. 9433-9445 ◽  
Author(s):  
Thomas J. Kucharski ◽  
Timothy F. Ng ◽  
David M. Sharon ◽  
Pedram Navid-Azarbaijani ◽  
Mahvash Tavassoli ◽  
...  

ABSTRACTChicken anemia virus (CAV) is a single-stranded circular DNA virus that carries 3 genes, the most studied of which is the gene encoding VP3, also known as apoptin. This protein has been demonstrated to specifically kill transformed cells while leaving normal cells unharmed in a manner that is independent of p53 status. Although the mechanistic basis for this differential activity is unclear, it is evident that the subcellular localization of the protein is important for the difference. In normal cells, apoptin exists in filamentous networks in the cytoplasm, whereas in transformed cells, apoptin is present in the nucleus and appears as distinct foci. We have previously demonstrated that DNA damage signaling through the ataxia telangiectasia mutated (ATM) pathway induces the translocation of apoptin from the cytoplasm to the nucleus, where it induces apoptosis. We found that apoptin contains four checkpoint kinase consensus sites and that mutation of either threonine 56 or 61 to alanine restricts apoptin to the cytoplasm. Furthermore, treatment of tumor cells expressing apoptin with inhibitors of checkpoint kinase 1 (Chk1) and Chk2 causes apoptin to localize to the cytoplasm. Importantly, silencing of Chk2 rescues cancer cells from the cytotoxic effects of apoptin. Finally, treatment of virus-producing cells with Chk inhibitor protects them from virus-mediated toxicity and reduces the titer of progeny virus. Taken together, our results indicate that apoptin is a sensor of DNA damage signaling through the ATM-Chk2 pathway, which induces it to migrate to the nucleus during viral replication.IMPORTANCEThe chicken anemia virus (CAV) protein apoptin is known to induce tumor cell-specific death when expressed. Therefore, understanding its regulation and mechanism of action could provide new insights into tumor cell biology. We have determined that checkpoint kinase 1 and 2 signaling is important for apoptin regulation and is a likely feature of both tumor cells and host cells producing virus progeny. Inhibition of checkpoint signaling prevents apoptin toxicity in tumor cells and attenuates CAV replication, suggesting it may be a future target for antiviral therapy.


PLoS ONE ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. e0170903 ◽  
Author(s):  
Yoshimi Endo Greer ◽  
Bo Gao ◽  
Yingzi Yang ◽  
Andre Nussenzweig ◽  
Jeffrey S. Rubin

2009 ◽  
Vol 8 (1) ◽  
pp. 45-54 ◽  
Author(s):  
Leslie A. Parsels ◽  
Meredith A. Morgan ◽  
Daria M. Tanska ◽  
Joshua D. Parsels ◽  
Brian D. Palmer ◽  
...  

PLoS Genetics ◽  
2013 ◽  
Vol 9 (4) ◽  
pp. e1003310 ◽  
Author(s):  
Carla Manuela Abreu ◽  
Ramesh Kumar ◽  
Danielle Hamilton ◽  
Andrew William Dawdy ◽  
Kevin Creavin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document